skip to main content

Hepatitis C — SCE Infectious Diseases MCQ

Instant feedback + full explanation. One question, done properly.

HardHepatitisHepatitis CSCE Infectious Diseases

A treatment-naive patient has HCV genotype 3, compensated cirrhosis and baseline NS5A Y93H resistance. There is no decompensation and ribavirin is not contraindicated. Which regimen best addresses this resistance-associated high-risk subgroup?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: A — Sofosbuvir/velpatasvir for 12 weeks plus weight-based ribavirin

The best answer is “Sofosbuvir/velpatasvir for 12 weeks plus weight-based ribavirin”. Genotype 3 compensated cirrhosis with baseline Y93H is a higher-risk subgroup. EASL supports sofosbuvir/velpatasvir for 12 weeks with weight-based ribavirin when tolerated. The 8-week voxilaprevir regimen and shortened or ribavirin-free alternatives do not match the recommended resistance-conscious plan.

Reference: EASL hepatitis C recommendations: https://easl.eu/publication/easl-recommendations-on-treatment-of-hepatitis-c/